- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03297762
Increasing Use of Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes
April 16, 2020 updated by: Darrell M Wilson, Stanford University
Improving Adherence to Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes
To use an enhanced continuous glucose monitor (CGM) experience, including an automated CGM-electronic health record (EHR) data integration system, proactive interventions, and gamification techniques, to increase CGM use among publicly-insured youth with type 1 diabetes (T1D).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The investigators will use an automated data integration system to monitor hours per week the CGM is worn and target interventions/troubleshooting techniques as needed.
The investigators will use gamification techniques (i.e.
ability to gain points and achieve small rewards) to help encourage CGM use and potentially improve glycemic control in this at-risk population.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford Children's
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
13 years to 19 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- type 1 diabetes for more than 6 months
- on insulin pump or multiple daily injections without plans to change modality in next 6 months
- insured by CCS or Medi-Cal
- receiving care at Lucile Packard Children's Hospital or Stanford Children's Health outpatient clinics
- English or Spanish-speaking
Exclusion Criteria:
- major illness or condition that may alter glucose control or ability to complete the study including pregnancy, cystic fibrosis, cancer, liver disease, history of transplant, or hemoglobinopathy
- current oral glucocorticoid use
- prior use of a CGM system
- hemoglobin A1C <7.5% or >12%
- no wireless internet access
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gamification
Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
|
incentives/rewards and contact between standard visits
Dexcom G5 continuous glucose monitor
|
Active Comparator: Standard care
Use of continuous glucose monitor (Dexcom G5) per usual care.
|
Dexcom G5 continuous glucose monitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CGM use
Time Frame: baseline to 6 months
|
amount of time per week CGM is used
|
baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hgb A1c
Time Frame: baseline to 6 months
|
glycemic control as measured by Hgb A1c
|
baseline to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Maria Chang, MD, Stanford University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2018
Primary Completion (Actual)
May 1, 2019
Study Completion (Actual)
June 1, 2019
Study Registration Dates
First Submitted
September 25, 2017
First Submitted That Met QC Criteria
September 25, 2017
First Posted (Actual)
September 29, 2017
Study Record Updates
Last Update Posted (Actual)
April 20, 2020
Last Update Submitted That Met QC Criteria
April 16, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-36423
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type1diabetes
-
Silesian Centre for Heart DiseasesThe Jerzy Kukuczka Academy of Physical Education in KatowiceCompletedtype1diabetesPoland
-
Vastra Gotaland RegionCompletedType1diabetesSweden
-
Rabin Medical CenterThe Leona M. and Harry B. Helmsley Charitable Trust; DreaMed DiabetesRecruiting
-
University of Southern CaliforniaThe Leona M. and Harry B. Helmsley Charitable TrustCompletedType1diabetesUnited States
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR)Active, not recruiting
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandCompletedType1diabetes | Hemodialysis | Type2DiabetesDenmark
-
Vastra Gotaland RegionRecruitingType1diabetes | Psychology Functional BehaviorSweden
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Active, not recruitingHypoglycemia | Type1diabetes | Islet Cell Transplantation | Hypoglycemia UnawarenessUnited States
-
University of British ColumbiaJuvenile Diabetes Research Foundation; Brain CanadaNot yet recruiting
Clinical Trials on gamification
-
VA Office of Research and DevelopmentEnrolling by invitation
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
University of TorontoUnknownMobile Applications | Diet, Healthy | Behavior, HealthCanada
-
University of PennsylvaniaCompletedAtherosclerotic Cardiovascular DiseaseUnited States
-
Municipality of SantiagoPontificia Universidad Catolica de Chile; University of Chile; Ministry of Health... and other collaboratorsUnknown
-
The University of Tennessee, KnoxvilleNot yet recruitingObesity, Childhood | Nutrition, Healthy
-
University of PennsylvaniaNot yet recruitingCoronary Artery Disease | Heart Failure | Hypertension | Obesity | Dyslipidemias | Coronary Heart Disease | Diabete MellitusUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)Enrolling by invitationHeart Failure | Hypertension | Diabetes | Mobility Limitation | Ambulatory DifficultyUnited States
-
University of PennsylvaniaCompleted
-
The University of QueenslandTerminatedGastroenteritis | Influenza | COVID